

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.

Heather Scharpenseel, Annkathrin Hanssen, Sonja Loges, Malte Mohme, Christian Bernreuther, Sven Peine, Katrin Lamszus, Yvonne Goy, Cordula Petersen, Manfred Westphal, Markus Glatzel, Sabine Riethdorf, Klaus Pantel, Harriet Wikman*
University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; *corresponding author: h.wikman@uke.de


INTRODUCTION

Liquid biopsy is the hot topic in cancer personalized medicine.

In Non-Small Lung Cancer (NSCLC) Circulating Tumour Cells (CTCs) are detected in rather few patients and numbers with the FDA-approved EpCam (epithelial marker) based CellSearch® system and other current methods. Therefore, the aim of this study is to establish an EpCAM-independent CTC isolation technique by using the two clinically relevant epithelial markers *EGFR* & *HER3* for CTC enrichment.

MATERIAL & METHODS

Magnetic Cell Separation (MACS)




Patient cohort
n=45; median age (range): 63 y (41 – 85)

Gender %		Histological type		Metastases	
f	35.4	SCC	3	Single	14
m	64.6	ADC	41	Multiple	27
		LCC	1	M0	4


EGFR mut		UICC Stage	
Exon 19	7 del	III	5
wt	30	IV	40
Not screened			

I. STEP: IMMUNOHISTOCHEMISTRY

- Background: EGFR and HER3 (member ErbB protein family) are overexpressed in brain metastases of NSCLC patients^{1,2}




II. STEP: MACS




Significantly higher detection rates when combining the methods in comparison to either single use CellSearch ($p = 0.0023$) or magnetic cell separation with EGFR/HER3 ($p = 0.0109$).

CTC enumeration



III. STEP: Mutation detection



Molecular analysis of primary lung tumor tissue (PT), corresponding circulating tumor cell cluster and three single CTCs to proof tumourigenic origin. MassARRAY system (iPLEX Lung) shows heterozygous mutation for KRAS G12S in PT. (A) Same mutation is seen in the CTC cluster (B) and in one single CTC (C), whereas two single CTCs (D,E) show no mutation for KRAS.

CONCLUSION

- EGFR and HER3 are suitable markers for the detection of CTC in NSCLC patients
- CTC isolation with the combination of EGFR/HER3 enrichment and the CellSearch® system allows CTC identification in a significantly higher fraction than either method alone (significant negative correlation by Cohen's kappa = -0.280)
- Isolated CTCs are suitable for downstream molecular characterization
- Challenge in NSCLC: heterogeneity → further research for the identification of subpopulations
- Implementation of multi-centred studies needed



1. Anstellungsverhältnis oder Führungsposition: keine

2. Beratungs- bzw. Gutachtertätigkeit: keine

3. Besitz von Geschäftsanteilen, Aktien oder Fonds: nein

4. Patent, Urheberrecht, Verkaufslizenz: keine

5. Honorare: keine

6. Finanzierung wissenschaftlicher Untersuchungen: nein

7. Andere finanzielle Beziehungen: nein

8. Immaterielle Interessenkonflikte: nein